Trevi Therapeutics
TRVI
93 hedge funds and large institutions have $194M invested in Trevi Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 2 closing their positions.
2,417% more call options, than puts
Call options by funds: $453K | Put options by funds: $18K
800% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 2
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
21% more funds holding
Funds holding: 77 → 93 (+16)
17% more capital invested
Capital invested by funds: $167M → $194M (+$27.5M)
0.7% more ownership
Funds ownership: 79.37% → 80.07% (+0.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.79M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.45M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.8M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$364K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.91M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.08M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$775K |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
-$743K |
| 5 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$596K |
TRVI Hedge Fund Activity: Q3 2024 in Review
93 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2024, worth a combined $194M — up 17% from $167M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TRVI positions and 2 closed out — a net gain of 16 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $4.79M. The largest seller was Rosalind Advisors, cutting an estimated $1.91M.
- 93 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2024, up from 77 in Q2 2024.
- Funds reported $194M of Trevi Therapeutics stock for Q3 2024, up 17% quarter-over-quarter.
- 18 funds opened new Trevi Therapeutics positions in Q3 2024 and 2 closed out, a net change of +16 holders.
- The largest Trevi Therapeutics buyer in Q3 2024 was Vivo Capital, an estimated $4.79M added.
- The largest Trevi Therapeutics seller in Q3 2024 was Rosalind Advisors, an estimated $1.91M sold.
Based on aggregated 13F filings for Q3 2024.